Second-line therapy for castrate-resistant prostate cancer: a literature review. - Wikidata - wikimedia - TriplyDB

Second-line therapy for castrate-resistant prostate cancer: a literature review.

Second-line therapy for castrate-resistant prostate cancer: a literature review.

http://www.wikidata.org/entity/Q37925129

about

Genistein enhances the efficacy of cabazitaxel chemotherapy in metastatic castration-resistant prostate cancer cells.Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.

P2860

Q35844645-47290D08-7A30-4430-A614-3BAD8ADDBEBB Q38942142-D3E970C8-E4AD-49A6-A532-22DEDBD34339

P2860

Second-line therapy for castrate-resistant prostate cancer: a literature review.

http://www.wikidata.org/entity/Q37925129

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Second-line therapy for castrate-resistant prostate cancer: a literature review.

@en

Second-line therapy for castrate-resistant prostate cancer: a literature review.

@nl

type

label

Second-line therapy for castrate-resistant prostate cancer: a literature review.

@en

Second-line therapy for castrate-resistant prostate cancer: a literature review.

@nl

prefLabel

Second-line therapy for castrate-resistant prostate cancer: a literature review.

@en

Second-line therapy for castrate-resistant prostate cancer: a literature review.

@nl

P1433

Q37925129-B63451A7-3D3A-43AD-BD0B-6ECCACA3C585

P1476

Q37925129-778B69FA-9F75-49F5-BE8B-E65A07112815

P2093

Q37925129-03EC50DD-2215-4312-B7D7-36C2B10A1C34

Q37925129-30B94824-EABA-4769-9762-B8CE55A39930

Q37925129-4FDF3ED5-1814-4065-9B38-DE3833DBDCE0

P2860

Q37925129-0A1B31AF-E2B2-434C-841B-D5D13D74B6D1

Q37925129-1CF0C571-5A05-4C31-BBED-A41EF94D3651

Q37925129-1F786E50-ED7D-4478-891E-4DBA80C6A302

Q37925129-28643DF5-19AD-4AC7-B382-F7DF23B0AFD8

Q37925129-51204F7B-3D97-4364-AE2B-809F2B33B762

Q37925129-56BE0992-E05E-4BF1-AEF9-0C9053A00CCF

Q37925129-57A4E528-B98A-4057-9688-E817B24298CB

Q37925129-5A43978A-B682-4367-9258-4FCE2E080A5A

Q37925129-5E913201-5082-4925-B1C5-69571C060128

Q37925129-6984EA4B-CA3F-4AED-8A88-CEE8C622ABBE

P304

Q37925129-B71F02A1-1964-43C5-8F75-A51C748DCC98

P31

Q37925129-202F510B-FD14-4F43-B0E6-C7FF2427DBD9

P356

Q37925129-241A2DB3-8B8A-46DE-8C3E-3F08F4837FE6

P433

Q37925129-CDE930AE-90DA-45E3-935C-97DB75BEA113

P478

Q37925129-B4E719C0-E451-4A7A-A6AB-AEA7CF705FF3

P577

Q37925129-CEE655F7-C3A2-4C08-84BE-440167A10096

P5875

Q37925129-8392ABEF-5BF3-4EA7-BBF7-AD7A78D9E2DA

P698

Q37925129-A5292322-FE7C-4F2A-9DAF-C75D68F585F8

P356

J.1743-7563.2011.01421.X

P1433

Asia Pacific Journal of Clinical Oncology

P1476

Second-line therapy for castrate-resistant prostate cancer: a literature review.

@en

P2093

E Hovey

http://www.w3.org/2001/XMLSchema#string

G Marx

http://www.w3.org/2001/XMLSchema#string

S C-H Kao

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer.

Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer.

Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.

Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer?

P304

212-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1743-7563.2011.01421.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51612725

http://www.w3.org/2001/XMLSchema#string

P698

21884433

http://www.w3.org/2001/XMLSchema#string